Company profile

Ticker
ILEIQ
Exchange
CEO
John M. Maslowski
Employees
Incorporated in
Location
Fiscal year end
Former names
American Financial Holding Inc, Isolagen Inc
SEC CIK
IRS number
870458888

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

14 Nov 19
7 Jul 20
31 Dec 20

News

Company financial data Financial data

Quarter (USD) Sep 19 Jun 19 Mar 19 Dec 18
Revenue 1.02M 21.79M 0 0
Net income -7.2M 11.74M -3.67M -1.62M
Diluted EPS -0.76 1.12 -0.4 -0.14
Net profit margin -707% 53.89%
Operating income -4.36M 13.57M -3.86M -3.23M
Net change in cash -6.93M 2.38M -3.11M -1.68M
Cash on hand 6.77M 13.7M 11.32M 14.43M
Cost of revenue 1.69M 5.17M 0
Annual (USD) Dec 18 Dec 17 Dec 16 Dec 15
Revenue 0 0 355K 492K
Net income -10.28M -16.24M -15.29M -34.45M
Diluted EPS -1.45 -6.67 -1.18 -0.85
Net profit margin -4308% -7003%
Operating income -12.39M -18.98M -26.48M -37.41M
Net change in cash -2.99M -98K -11.75M -8.23M
Cash on hand 14.43M 17.42M 17.52M 29.27M
Cost of revenue 0 697K 722K

Financial data from company earnings reports

Date Owner Security Transaction Code 10b5-1 $Price #Shares $Value #Remaining
13 Dec 19 Julian P. Kirk Option to Purchase Common Stock Common Stock Sale back to company Dispose D No 16.55 6,000 99.3K 0
13 Dec 19 Kirk Randal J Common Stock Dispose U No 3 539,337 1.62M 0
13 Dec 19 Kirk Randal J Common Stock Dispose U No 3 1,324,328 3.97M 0
13 Dec 19 Kirk Randal J Common Stock Conversion Aquire C No 0 169,602 0 1,324,328
13 Dec 19 Kirk Randal J Common Stock Dispose U No 3 2,453 7.36K 0
13 Dec 19 Kirk Randal J Common Stock Conversion Aquire C No 0 291 0 2,453
13 Dec 19 Kirk Randal J Common Stock Dispose U No 3 80,160 240.48K 0
13 Dec 19 Kirk Randal J Common Stock Conversion Aquire C No 0 10,282 0 80,160
13 Dec 19 Kirk Randal J Series A Convertible Preferred Stock Common Stock Conversion Dispose C No 0 1,161 0 0
13 Dec 19 Kirk Randal J Series A Convertible Preferred Stock Common Stock Conversion Dispose C No 0 1,746 0 0
13F holders
Current Prev Q Change
Total holders 1 22 -95.5%
Opened positions 0 5 EXIT
Closed positions 21 3 +600.0%
Increased positions 0 4 EXIT
Reduced positions 0 2 EXIT
13F shares
Current Prev Q Change
Total value 0 10.6M EXIT
Total shares 0 3.58M EXIT
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners
Shares Value Change
Proequities 0 $0
Largest transactions
Shares Bought/sold Change
Third Security 0 -1.65M EXIT
Renaissance Technologies 0 -763.75K EXIT
Vanguard 0 -395.63K EXIT
Beryl Capital Management 0 -298.28K EXIT
MSD Partners 0 -138.59K EXIT
Susquehanna International 0 -107.07K EXIT
Geode Capital Management 0 -97.04K EXIT
MS Morgan Stanley 0 -49.9K EXIT
Creative Planning 0 -13.4K EXIT
Cambridge Investment Research Advisors 0 -12.62K EXIT

Financial report summary

?
Risks
  • Failure to complete the Merger could negatively impact the price of our common stock, as well as our future business and financial results.
  • The Merger Agreement limits our ability to pursue alternatives to the Merger and may discourage other companies from trying to acquire us for greater consideration than what CCP Holdings has agreed to pay.
  • The CCP License Agreement is important to our business. If we or CCP fail to adequately perform under the CCP License Agreement, or if we or CCP terminate the CCP License Agreement, the development and commercialization of FCX-007 would be delayed or terminated and our business would be adversely affected.
Management Discussion
  • Item 2.  Management’s Discussion and Analysis of Financial Condition and Results of Operations.
  • We are a cell and gene therapy company focused on improving the lives of people with rare diseases of the skin and connective tissue. We are utilizing our proprietary autologous fibroblast technology to develop personalized biologics that target the underlying cause of disease.  Fibroblasts are the most common cell in skin and connective tissue and are responsible for synthesizing extracellular matrix proteins, including collagen and other growth factors, that provide structure and support. Because fibroblasts naturally reside in the localized environment of the skin and connective tissue, they represent an ideal delivery vehicle for proteins targeted to these areas.  We target the underlying cause of disease by using fibroblast cells from a patient’s skin and genetically modifying them to create localized therapies that are compatible with the unique biology of the patient (i.e., which are autologous).
  • Our pipeline of localized gene therapy candidates include FCX-007 for the treatment of recessive dystrophic epidermolysis bullosa (RDEB), a life-threatening genetic disorder diagnosed in infancy with no cure or treatment approved by the U.S. Food and Drug Administration (FDA). We are also developing FCX-013 for the treatment of moderate to severe localized scleroderma. Currently, all of our research and development operations and focus are on gaining regulatory approvals to commercialize our gene therapy candidates in the United States; however, we may seek to expand into international markets in the future.
Content analysis ?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: accuracy, acquire, acquired, affirm, al, allege, alleged, appraisal, arising, assert, Braschuk, Burnaska, challenging, competing, complaint, complying, confidentiality, counsel, Court, Del, Delaware, demanding, detrimental, discourage, District, employment, entry, fact, false, forbear, Franchi, improperly, injunction, Joe, Kaboom, Kapital, lawsuit, Mascara, Master, merge, merit, misleading, MSD, multiplied, notification, NRM, Opportunity, Pharmaceutical, plaintiff, preliminary, premium, prohibition, promulgated, proxy, publicly, purported, purpose, pursuit, recommend, recommendation, refrain, regular, signature, soliciting, Southern, spent, styled, survive, surviving, tender, vi, vigorously, violated, waived, withdraw, withhold, York
Removed: comparable